PEB - Pacific Edge Ltd

[angrytoenail]

Locked article on the NBR;
www.nbr.co.nz/article/why-pacific-edge-sees-itself-guinea-pig-better-healthcare-db-p-151703

Anyone got access who could summarise??
Thanks

Here you go:

Ask David Darling to quantify financially what it means to have CxBladder adopted by the main district health boards (DHBs) and he remains guarded.

But the Pacific Edge [NZX: PEB] chief executive reckons having the backing of government agencyHealth Innovation Hub (HIH) for his company’s bladder cancer detection system is a tipping point for faster, better and sharper healthcare in New Zealand.

HIH has signed an agreement to fast track the introduction of Pacific Edge’s CxBladder technology to the four main DHBs, which cover half this country’s population.

The agreement is part of a move by the Ministry of Health to help push new technology into the mainstream, a process that is invariably bogged down by the clunky nature of the health system, Mr Darling says.

“This is recognition by the ministry that new technology just doesn’t get into these DHBs and the advantages and benefits to the New Zealand healthcare system are not being actioned because of this slow pathway in,” he says.

“We now have a dedicated agent on our product in each of those key jurisdictions and hopefully we will see a lot of these challenges that we’ve been running up against removed from our process.”

Pacific Edge's Cx-bladder uses a non-invasive urine sample for testing. It has certified labs in Pennsylvania and Dunedin that can respectively process up to 260,000 and 35,000 tests annually.

Being the guinea pig

The next step, Mr Darling says, may be to have the testing tool mandatorily accepted as the standard of care in New Zealand. That would give the company enormous marketing power in the US.

“That’s another happening and something we are working on,” Mr Darling says.

What he can say is that the product has already been evaluated by most DHBs and been validated through 200 patient user programmes.

“So it’s not about whether we want it, it’s about who pays and how we get it into the system.”

“We talk about wading through treacle and while it's nice and sweet, it’s damn hard work.

“The great thing for us now is there is a strong push coming from all around New Zealand and we are genuinely the guinea pig for this process because we are such a cute, clean technology with lots of upside.

“So they want to use this technology to change the processes to make the system faster sharper, better.”

Big savings

Mr Darling says CxBladder has the ability to deliver “significant savings in time and expense” for DHBs.

“If we are able to segregate one patient who doesn’t need a full workup, then the direct cost recovery to the DHB could be in excess of several thousand dollars.”

Then there are indirect costs such as the reallocation of resources – some patients are in queues for up to three months, he says.

The new Cxbladder diagnostic test costs around about $320, while a conventional full, invasive clinical test in New Zealand can cost between $1750 and $2200.

HIH was recently formed, with a mandate to enable technology commercialisation into and out of the country’s four largest DHBs.

HIH chief executive Frances Guyett says identifying and forming strategic relationships with key external partners to accelerate commercialisation by enabling access to DHBs is one of the HIH’s key objectives.

[stoploss]

you are probably right that trading high does not show up on the asb charts just another reason why I need to change to direct broking.

just for good order traded to 1.76 on FEb 3.

[Slam dunk]

Here you go:

Like this part in particular

Being the guinea pig

The next step, Mr Darling says, may be to have the testing tool mandatorily accepted as the standard of care in New Zealand. That would give the company enormous marketing power in the US.

“That’s another happening and something we are working on,” Mr Darling says.

[winner69]

Like this part in particular

Being the guinea pig

The next step, Mr Darling says, may be to have the testing tool mandatorily accepted as the standard of care in New Zealand. That would give the company enormous marketing power in the US.

“That’s another happening and something we are working on,” Mr Darling says.

but this is the nicest bit

....because we are such a cute, clean technology with lots of upside.

How sweet, I just love cute things

[MAC]

Like this part in particular

Being the guinea pig

The next step, Mr Darling says, may be to have the testing tool mandatorily accepted as the standard of care in New Zealand. That would give the company enormous marketing power in the US.

“That’s another happening and something we are working on,” Mr Darling says.

You're on the money Slam Dunk, this will be worth more to PEB than the few millions in revenues they will extract from the four or five million people inhabiting our humble islands.

The ability of Pacific Edge to hopefully demonstrate precedence internationally of the inclusion of Cxbladder into a national 'gold standard' is really the significant potential outcome of this relationship with the HIH.

It bodes well too for the ‘hot housing’ of the other pipeline products here also, hopefully Cxcolorectal becomes the next HIH agreement sometime this year.

[Harvey Specter]

Personally I like this one:

We talk about wading through treacle and while it's nice and sweet, it’s damn hard work.

With quotes like that, and an increasing share price, they will get lots of news coverage, just like Drury does for XRO.

[clip]

What were you saying about announcements coming in 2's moosie? (apologies for big post below, announcement copied)

https://nzx.com/companies/PEB/announcements/246862
BOP & Lakes Urologists adopt Cxbladder

12:35pm, 11 Feb 2014 | GENERAL

11 February 2014
BOP and Lakes Urologists adopt Cxbladder
Patients presenting with symptoms of bladder cancer and those under surveillance of bladder cancer in the Bay of Plenty and Lakes District Health Board regions will now be evaluated as part of their clinical program, with Pacific Edge’s non-invasive urine sampling Cxbladderdetect test.
Bay of Plenty and Lakes District urologists are the latest to join the list of New Zealand clinicians and DHB’s who are being signed by Pacific edge Diagnostics to offer their patients Cxbladderdetect. Cxbladder is a superior technology with its ability to detect nearly 100 per cent of urinary tract carcinomas , in preference to cytology for the detection and monitoring of patients who may have bladder cancer.
Like MidCentral DHB, which began using Cxbladderdetect in June, BOP urologists will use Cxbladderdetect to evaluate patients presenting with blood in the urine (haematuria) as part of their clinical regime. This new strategy is expected to involve local GPs (the patient’s primary point of contact when symptoms occur) using Cxbladderdetect to help prioritise those patients who need to be seen urgently. They will also be able to identify low risk patients who do not require a full clinical work-up for bladder cancer, saving the public health system considerable associated expense, not to mention the inconvenience to the patients. Less than one in twenty of those patients with micro-haematuria are found to need further treatment for bladder cancer.
Pacific Edge is a Dunedin-based cancer diagnostic company leading in the development and commercialisation of molecular diagnostic tests. Pacific Edge Chief Executive Officer David Darling says there are significant potential savings to be made in the New Zealand health budget if all DHBs adopt Cxbladderdetect for the early evaluation and further analysis of patients presenting with haematuria.
“Many New Zealanders may have heard Sir Peter Leitch talk on television last year about the ease of use and high degree of confidence he and his clinician had in Cxbladderdetect (http://tvnz.co.nz/national-news/nz-c...-video-5234521) for monitoring his recovery from bladder cancer”. Those benefits are now being made available to nearly half a million New Zealanders [488,280 : pop numbers from MOH website] within the BOP, Lakes regions and the Mid Central DHB.

“Cxbladderdetect will allow clinicians in these three regions to provide better clinical outcomes for patients referred for urological evaluation and contribute considerable efficiencies for patients and healthcare providers, from its use.”
Bay of Plenty urologist, Mark Fraundorfer says that now is the right time to start using Cxbladderdetect. “Pacific Edge have gathered the clinical data and published in a peer reviewed journal, and the superior performance over cytolgy is clear. BOP (and Lakes) urologists have used Cxbladderdetect in a variety of clinivcal settings in both public and our private clinics over the last nine months, confirming the performance of the technology. Cxbladderdetect provides better information about the patients being referred to urologists and allows us to increase our focus on the patients that need further evaluation and treatment, and will avoid a significant number of unnecessary procedures. This is a good outcome for both the patients and the public health system as a whole.”
A recently completed clinical user programme involving 178 patients undertaken by Waitemata District Health Board and Urology Associates in conjunction with Canterbury DHB has confirmed the successful results of a multi-centre international peer reviewed study of 485 patients published in the prestigious American Journal of Urology in September 2012. Both studies showed that Cxbladderdetect identified correctly nearly 100 per cent of tumours of concern to clinicians, including those that cytology and several that cystoscopy did not identify. The results of the two centre New Zealand user programme are expected to be formally published later this year.
For clinicians and DHBs focused on providing the very best cost effective healthcare for New Zealanders, Cxbladderdetect provides a number of significant advantages that have the potential to change clinical practice and lower the overall cost of managing the patient’s disease:
• The Cxbladderdetect Urine Sampling System (USS) can be sent directly to the patient at home or to their GP clinic, thereby reducing waiting times to see a specialist within the public hospital system.
• Cxbladderdetect provides an accurate and cost effective way of evaluating patients presenting with blood in their urine (haematuria), before they get to the clinic and
• Cxbladderdetect is non-invasive and enhances a patient’s compliance with their cancer management regime as defined by the urologist.
For further information please contact
David Darling
Chief Executive Officer
Pacific Edge Limited
P: +64 (3) 4795800

After a quick skim this point seems prominent to me, "Like MidCentral DHB, which began using Cxbladderdetect in June, BOP urologists will use Cxbladderdetect to evaluate patients presenting with blood in the urine (haematuria) as part of their clinical regime. This new strategy is expected to involve local GPs (the patient’s primary point of contact when symptoms occur) using Cxbladderdetect to help prioritise those patients who need to be seen urgently."

I would have thought getting the tests in at the GP level would result in higher number of tests being utilized quicker as opposed to just when they have been referred to DHB clinics/hospitals etc

[whatsup]

the real importance of this ann is the confirmation from dhb's that cxbladder is the test to run with , imho all dhb's (world wide ) will follow this practise ! .

another brick in the wall !!!

[Harvey Specter]

I would have thought getting the tests in at the GP level would result in higher number of tests being utilized quicker as opposed to just when they have been referred to DHB clinics/hospitals etc

I read that as the DHB wont take a referral unless they have done the test, as it is used to prioritize patients. Therefore very positive as it means it will be pushed out fast.

What does concern me is if MidCentral has been using since June, why were there so few sales in the September update.

[Xerof]

It's all about momentum, isn't it? As we have collectively determined, it's not a lot of revenue, when compared to the golden fleece, but we have momentum. The first pebble has hit the lake surface - waiting for the ripples now